year
research
sinc
first
identifi
pari
great
advanc
understand
viru
immun
system
practic
advanc
includ
earli
develop
diagnost
test
infect
made
blood
donat
safe
sinc
combin
antiretrovir
therapi
great
reduc
incid
aid
hivinfect
peopl
access
drug
hiv
prevent
behaviour
chang
success
yet
safe
efficaci
microbicid
vaccin
fit
anniversari
discoveri
look
back
past
achiev
look
forward
daunt
challeng
still
face
order
overcom
aid
pandem
perspect
shall
foolhardi
attempt
provid
comprehens
review
hiv
aid
recommend
jay
levi
book
rather
provid
person
view
salient
discoveri
remain
gap
knowledg
cours
magnific
advanc
diagnosi
therapi
gain
insight
immunopathogenesi
aid
howev
despit
sustain
effort
mani
talent
investig
still
appear
near
start
block
control
hiv
prevent
appear
novel
type
immun
defici
presag
summer
hand
young
homosexu
men
new
york
san
francisco
lo
angel
diagnos
pneumocysti
carinii
pneumonia
kaposi
sarcoma
ks
epidemiologist
center
diseas
control
prevent
atlanta
detect
unusu
cluster
patient
set
investig
proven
soon
recogn
underli
immun
defici
gay
compromis
syndrom
associ
select
deplet
helper
cell
becam
appar
must
infecti
agent
induc
diseas
also
found
inject
drug
user
recipi
blood
transfus
thu
diseas
acquir
name
acquir
immun
defici
syndrom
manifest
aid
patient
haemophilia
specul
kind
viru
caus
microb
unlik
taint
pool
clot
factor
fact
epidemiologist
elucid
risk
group
mode
transmiss
accur
discoveri
hiv
earli
day
aid
diseas
patient
often
knew
doctor
aid
affect
gay
men
disproportion
articul
welleduc
assert
bodi
peopl
strong
network
could
ask
awkward
question
challeng
whiff
patron
attitud
among
physician
establish
advocaci
group
lobbi
social
medic
issu
affect
hiv
aid
gay
men
risk
aid
pioneer
electron
exchang
medic
knowledg
commonplac
sourc
inform
diseas
curiou
coincid
burgeon
hiv
pandem
parallel
exponenti
expans
internet
downsid
worldwid
web
also
superb
medium
perpetu
myth
hiv
denial
blame
conspiraci
theori
concern
aid
tragedi
siren
voic
socal
aid
dissid
sympathi
leader
nation
hivinfect
peopl
despit
effort
correct
situat
may
colleagu
pari
led
luc
montagni
institut
pasteur
publish
descript
previous
unknown
viru
isol
patient
lymphadenopathi
call
bru
viru
replic
associ
revers
transcriptas
rt
activ
assum
retroviru
fig
viru
cytopath
could
propag
seriallywith
tender
love
care
low
titr
ad
medium
harvest
die
cultu
fresh
cultur
activ
peripher
blood
mononuclear
cell
pbmc
would
call
bru
primari
isol
tropism
primari
cell
macrophag
express
grow
cell
line
express
retrospect
insuffici
note
initi
taken
paper
one
mani
candid
infecti
agent
inde
accompani
paper
issu
scienc
bob
gallo
max
essex
group
suggest
anoth
type
retroviru
human
cell
leukaemia
viru
possibl
caus
aid
detect
genuin
enough
hindsight
turn
passeng
viru
patient
immunodefici
april
montagni
group
publish
hiv
isol
includ
one
aid
patient
lai
grew
much
higher
titr
call
isol
grow
cell
leukaem
cell
line
express
addit
montagni
electron
microscop
studi
indic
hiv
resembl
anim
lentivirus
rather
deltavirus
interpret
vindic
firmli
simon
wainhobson
colleagu
sequenc
interpret
correctli
open
read
frame
genom
hiv
prototyp
lentiviru
maedivisna
viru
mvv
sheep
shortli
montagni
second
public
hiv
lai
gallo
popov
nation
institut
health
nih
levi
san
francisco
publish
isol
hiv
group
gave
viru
differ
name
eventu
dna
clone
genom
sequenc
still
labouri
process
confirm
virus
belong
singl
speci
reveal
genuin
differ
isol
surprisingli
variabl
sequenc
genom
divers
later
allow
wainhobson
perform
neat
forens
dna
analysi
lai
isol
becom
opportunist
contamin
agent
sever
laboratori
includ
mine
aid
viru
various
call
lav
idav
htlviii
arv
term
hiv
coin
intern
committe
chair
harold
varmu
sought
ration
confus
terminolog
oddli
enough
consortium
investig
london
first
demonstr
gallo
montagni
studi
type
viru
rachane
cheingsongpopov
brought
lai
pari
laboratori
februari
obtain
iiib
nih
month
later
found
virus
grew
high
titr
cem
cell
line
richard
tedder
establish
competit
radioimmun
assay
employ
hiv
antigen
cem
cell
detect
serum
antibodi
british
patient
aid
subject
aid
risk
group
collect
brian
gazzard
toni
pinch
jonathan
weber
ian
weller
sampl
react
posit
virus
levi
found
lav
arv
perform
simpl
oldfashion
experi
use
immunofluoresc
antibodi
absorb
onto
excess
cell
infect
htlviii
reactiv
lai
also
remov
serum
sampl
serolog
test
help
establish
aid
western
diseas
spread
rapidli
africa
patient
symptom
similar
hiv
note
sex
congo
rwanda
montagni
group
isol
hiv
one
uganda
peopl
realiz
novel
afflict
first
appear
among
wake
milton
obot
armi
liber
countri
idi
amin
grip
open
truck
rout
trader
call
slim
diseas
wast
syndrom
diarrhoea
notabl
symptom
although
ks
alway
rel
frequent
tumour
africa
new
aggress
form
young
adult
sprung
togeth
ann
bayley
lusaka
david
serwadda
nelson
sewankambo
kampala
show
serolog
aggress
ks
slim
diseas
associ
hiv
infect
first
thought
antibodi
test
suffici
specif
control
sera
taken
healthi
hospit
staff
yield
posit
result
awesom
moment
penni
drop
realiz
realli
infect
disastr
spread
hiv
southern
africa
even
higher
preval
rate
occur
later
recent
unaid
estim
million
peopl
worldwid
live
hiv
infect
count
million
alreadi
die
aid
recogn
although
overal
estim
global
hiv
preval
fallen
recent
year
owe
refin
monitor
method
hiv
mortal
overtaken
malaria
supersed
tobacco
compar
identif
sar
coronaviru
three
independ
group
path
discoveri
hiv
year
earlier
appear
tent
errat
howev
molecular
techniqu
revers
transcriptionpolymeras
chain
reaction
rtpcr
yet
avail
viru
isol
need
fastidi
cultur
lymphocyt
less
easi
appli
classic
evid
koch
postul
ill
long
incub
period
nevertheless
year
recognit
aid
new
diseas
western
countri
year
pioneer
first
descript
et
al
suffici
incrimin
evid
satisfi
juri
epidemiologist
virologist
immunologist
everyon
els
viru
guilti
beyond
reason
doubt
caus
aid
use
anim
model
human
diseas
well
recogn
insight
may
gain
pathogenesi
investig
candid
drug
vaccin
howev
found
like
hepat
b
viru
abl
infect
chimpanze
even
close
rel
human
succumb
aid
convent
intern
trade
endang
speci
wild
flora
fauna
endang
speci
experiment
infect
great
ape
soon
embargo
therefor
simian
immunodefici
virus
siv
macaqu
becam
one
experiment
model
hiv
recent
recombin
hybrid
hivsiv
virus
known
shiv
develop
challeng
test
vaccin
worth
recal
sivmac
discov
year
felin
immunodefici
viru
around
time
one
state
without
much
ironi
hiv
great
model
veterinari
lentiviru
infect
natur
infect
chimpanze
sivcpz
discov
genom
organ
sequenc
similar
reveal
sivcpz
natur
precursor
recent
investig
indic
chimpanze
subspeci
locat
gabon
like
origin
group
pandem
strain
wherea
group
orel
siv
present
chimpanze
gorilla
like
sivcpz
becom
sivsm
recent
cross
speci
sooti
mangabey
rhesu
cynomolgu
macaqu
sivmac
human
emerg
sivmac
occur
captiv
presum
african
asian
speci
hous
togeth
primat
centr
unit
state
like
sivmac
pathogen
new
host
wherea
sivsm
caus
littl
harm
mangabey
elucid
proven
sivmac
play
role
discoveri
max
essex
suleyman
mboup
found
serum
sampl
senegales
patient
aidslik
symptom
react
strongli
siv
montagni
group
isol
success
patient
cap
verd
island
seneg
appear
sivsm
transfer
mangabey
human
west
africa
least
six
occas
said
less
pathogen
human
much
slower
progress
aid
sens
true
tend
lower
viral
load
less
transmiss
mothertochild
transmiss
demonstr
howev
develop
aid
bimod
major
infect
peopl
west
africa
becom
ill
genuin
longterm
nonprogressor
wherea
minor
progress
aid
much
rate
untreat
individu
whether
viru
host
determin
differ
cours
infect
yet
understood
opinion
research
merit
attent
genet
divers
hiv
becom
legendari
group
radiat
subtyp
ak
numer
circul
recombin
form
fig
quasispeci
genom
singl
individu
year
infect
larg
global
variat
influenza
viru
rapid
practic
health
outcom
follow
discoveri
hiv
develop
blood
test
determin
infect
late
sever
diagnost
kit
market
detect
specif
antibodi
hiv
treatment
infect
benefit
individu
know
hiv
statu
debat
screen
blood
donor
howev
immedi
public
health
benefit
antibodi
detect
still
left
period
infect
seroconvers
individu
becam
infecti
other
window
first
fill
test
antigen
plasma
subsequ
twentyf
year
hiv
develop
rtpcr
detect
viral
genom
quantit
rtpcr
relat
techniqu
led
measur
plasma
viral
load
prove
use
prognost
marker
guid
clinic
manag
effect
antiretrovir
drug
combin
introduc
later
genotyp
marker
drug
resist
also
prove
worth
thu
molecular
techniqu
detect
quantif
character
viral
genom
play
import
role
screen
treatment
pharmacolog
treatment
also
resound
success
access
first
antiretrovir
drug
go
clinic
trial
azidothymidin
zidovudin
chain
termin
nascent
dna
revers
transcript
phase
iii
trial
hivinfect
patient
unit
state
apear
promis
placebo
arm
stop
prematur
howev
anglofrench
concord
trial
show
drop
viral
load
benefit
patient
shortliv
owe
rapid
emerg
zidovudineresist
hiv
mutant
vivo
rt
inhibitor
proteas
inhibitor
introduc
recent
cellentri
inhibitor
integras
inhibitor
licens
thu
understand
molecular
event
viru
replic
cycl
led
ration
design
antiretrovir
drug
fig
develop
new
antiretrovir
drug
show
crossresist
zidovudin
took
sever
year
number
rt
inhibitor
proteas
inhibitor
develop
combin
three
drug
taken
togeth
era
highli
activ
antiretrovir
therapi
haart
born
effect
dramat
shown
fig
mortal
fell
almost
infecti
diseas
ward
hospit
empti
hiv
infect
becam
treatabl
condit
sexual
transmit
infect
sti
depart
physician
offic
even
overoptimist
specul
haart
might
erad
hiv
infect
person
bodi
wherea
fact
resurg
viral
replic
occur
soon
patient
take
drug
holiday
two
big
challeng
remain
first
hiv
patient
haart
eventu
acquir
multipl
resist
avail
drug
far
littl
evid
multipl
resist
occur
yet
increasingli
drugresist
hiv
strain
transmit
suscept
popul
therefor
novel
drug
drug
target
like
requir
continu
debat
start
antiretrovir
therapi
treatment
primari
infect
might
improv
initi
clearanc
infect
immun
respons
hiv
postpon
initi
treatment
late
stage
infect
may
delay
emerg
resist
second
larger
challeng
whether
haart
roll
greatest
need
treatment
often
poorest
countri
set
figur
show
haart
yet
dent
estim
aid
mortal
subsaharan
africa
asia
logist
deliv
haart
develop
countri
complex
provid
packet
pill
diagnosi
made
viral
load
cell
measur
help
inform
treatment
regimen
countri
welldevelop
health
system
expens
term
resourc
train
personnel
absenc
safe
efficaci
prophylact
vaccin
hiv
number
proxi
method
reduc
prevent
spread
hiv
promot
mix
result
abc
nostrum
us
aid
agenc
abstin
faith
ca
nt
use
condom
worthi
aspir
adher
difficult
especi
partner
refus
compli
favourit
safesex
slogan
harcon
aid
campaign
mumbai
kamasutra
prescript
hiv
prevent
state
mani
postur
one
better
one
mani
safe
sex
advic
gay
men
also
help
period
acquir
hiv
infect
place
death
row
indefinit
period
hope
releas
one
downsid
haart
diminish
perceiv
threat
hiv
treatabl
condit
clean
needl
syring
suppli
exchang
old
one
help
reduc
risk
parenter
transmiss
among
inject
drug
user
pragmat
approach
also
offend
moralist
view
needl
exchang
condon
even
encourag
illicit
drug
habit
introduc
western
europ
year
unit
state
one
imagin
intervent
triall
target
cofactor
exacerb
risk
hiv
transmiss
sti
neisseria
gonorrhea
haemophilu
ducreyi
caus
local
inflamm
ulcer
therefor
sti
associ
increas
hiv
transmiss
differ
trial
prophylat
use
inexpens
antibiot
acyclovir
control
genit
herp
yield
mix
result
reduc
hiv
incid
potenti
problem
prophylaxi
nonhiv
sti
select
resist
strain
bacteri
sti
may
eventu
emerg
male
circumcis
associ
lower
rate
hiv
transmiss
men
mucos
surfac
foreskin
rel
rich
hiv
target
cell
lymphocyt
langerhan
cell
addit
lack
circumcis
may
associ
frequent
longerlast
inflamm
sti
adventiti
infect
heighten
risk
hiv
acquisit
remark
see
recent
year
observ
epidemiolog
find
translat
intervent
trial
young
men
will
assign
random
blind
group
circumcis
intervent
result
show
signific
protect
effect
circumcis
much
interest
vagin
microbicid
could
appli
discreetli
women
prevent
transmiss
either
direct
unfortun
first
test
spermicid
nonoxynol
actual
increas
risk
infect
women
slight
inflammatori
effect
microbicid
polyaniom
macromolecul
yet
shown
efficaci
notion
chemic
block
hiv
transmiss
point
good
one
abandon
aid
first
recogn
immunologist
recent
distinguish
helper
cell
killer
effector
cell
use
surfac
antigen
discrimin
thu
soon
found
aid
associ
disappear
cell
peripher
blood
follow
discoveri
hiv
david
klatzmann
pari
show
vitro
hiv
replic
select
caus
cytopath
effect
cell
cell
allow
group
demonstr
antigen
bind
receptor
hiv
sequenc
find
seem
logic
retrospect
actual
reason
think
hiv
would
use
exactli
marker
chosen
clinic
immunologist
receptor
studi
benefit
fruit
collabor
peter
beverley
mel
greav
immunologist
virologist
dorothi
crawford
use
lymphocyt
cell
surfac
marker
avail
timesom
monoclon
antibodi
mab
cd
antigen
includ
mab
pinpoint
cdna
clone
abl
confirm
immunolog
find
transfect
studi
reveal
need
hiv
infect
suffici
hiv
bind
cell
surfac
compon
requir
viru
penetr
took
year
identifi
hiv
coreceptor
entri
factor
chemokin
receptor
first
clue
came
gallo
laboratori
found
cc
chemokin
regul
uopn
activ
normal
cell
express
secret
macrophag
inflammatori
protein
mip
ap
inhibit
hiv
infect
ed
berger
nih
discov
express
clone
coreceptor
cell
line
follow
quickli
identif
coreceptor
pbmc
macrophag
identifi
coreceptor
major
transmiss
strain
hiv
led
develop
entri
inhibitor
discern
polymorph
resist
factor
discuss
later
macrophag
first
shown
infect
hiv
susan
gartner
gallo
laboratori
dogma
time
retrovirus
could
replic
prolifer
cell
preintegr
complex
could
cross
nuclear
membran
requir
mitosi
access
chromosom
howev
prove
true
oncogen
retrovirus
lentivirus
vpu
core
protein
nuclear
locat
signal
fact
known
prototyp
lentiviru
mvv
sheep
infect
macrophag
helper
lymphocyt
opinion
observ
compar
virolog
provid
insight
hiv
pathogenesi
mvv
caus
sever
wast
diseas
neurodegener
pulmonari
dysfunct
cell
immunodefici
would
postul
therefor
wast
syndrom
well
aid
dementia
essenti
diseas
macrophag
human
aid
howev
sheep
suscept
mvv
suffer
remorselessli
progress
diseas
lead
death
repres
underli
pathogenesi
common
lentivir
infect
protect
cell
number
function
without
protect
macrophag
ultim
save
patient
target
dendrit
cell
dc
hiv
debat
infect
macrophag
england
stella
knight
claim
sinc
hiv
infect
dc
disbeliev
ralph
steinman
although
convert
controversi
resolv
larg
discern
differenti
sensit
two
type
dc
plasmacytoid
pdc
meyloid
mdc
distinct
lymphocyt
two
decad
earlier
help
pinpoint
suscept
hiv
infect
london
steve
patterson
show
mdc
express
henc
support
hiv
entri
replic
wherea
pdc
allow
bind
hiv
dcsign
without
viral
replic
except
possibl
strain
matur
nevertheless
attach
hiv
dcsign
allow
pdc
deliv
hiv
suscept
cell
upon
migrat
lymph
node
immunolog
synaps
pdc
cell
activ
helper
lymphocyt
make
permiss
hiv
replic
also
deliv
hiv
particl
across
synaps
typic
cours
hiv
shown
fig
primari
infect
via
mucos
parenter
rout
result
high
viraemia
accompani
sometim
symptom
fever
diarrhoea
lymphadenopathi
state
activ
replic
high
viru
load
resolv
lower
set
point
level
point
predict
rate
progress
aid
untreat
individu
higher
level
wors
prognosi
pictur
blood
howev
faint
imag
indic
much
higher
activ
lymphoid
tissu
shown
first
tennerracz
experiment
vagin
cervic
infect
macaqu
sivmac
show
local
replic
hiv
dermal
macrophag
dc
migrat
lymph
node
deliv
viru
helper
cell
alreadi
discuss
recent
find
show
activ
site
hiv
replic
earli
infect
largest
lymphoid
organ
mucos
associ
lymphoid
tissu
malt
gut
partial
clearanc
viru
follow
seroconvers
ascrib
often
cellmedi
immun
specif
cytotox
cell
first
appear
time
well
specif
cell
inde
patient
lowest
set
point
longest
surviv
socal
elit
control
infect
show
strongest
specif
cell
help
hiv
howev
featur
may
contribut
fall
viral
load
role
humor
immun
tend
ignor
neutral
antibodi
appear
month
seroconvers
forget
neutral
assay
repres
artifici
vitro
measur
protect
antibodi
vivo
antibodi
circul
pool
complement
colleagu
marlen
aasachapman
et
al
shown
hiv
inactiv
lysi
viral
envelop
specif
antibodi
occur
concomitantli
appear
cytotox
lymphocyt
fall
viral
load
find
corrobor
alexandra
trkola
group
similar
nonneutr
antibodi
may
also
destroy
hivinfect
cell
antidepend
cellular
cytotox
thu
humor
compon
clearanc
primari
infect
merit
seriou
consider
anoth
contributor
fall
viral
load
may
result
specif
immun
infect
cell
malt
sever
deplet
cell
suscept
hiv
infect
might
account
appar
clearanc
infect
convers
one
could
argu
abund
suscept
cell
permit
high
viru
load
peak
viraemia
never
reappear
therefor
interest
investig
proport
cell
malt
activ
state
support
hiv
replic
long
clinic
asymptomat
period
follow
seroconvers
decept
hiv
infect
latent
introduct
haart
provid
opportun
analys
dynam
viru
replic
cell
turnov
becam
appar
steadi
state
cell
count
actual
repres
balanc
rapid
cell
destruct
power
restor
within
immun
system
somewhat
like
watch
duck
glide
across
pond
without
see
activ
web
feet
eventu
capac
immun
regener
becom
exhaust
level
cell
drop
threshold
cellsml
opportunist
infect
overwhelm
patient
mani
aspect
hiv
pathogenesi
remain
investig
exampl
variant
aris
late
infect
seen
frequent
western
patient
infect
clade
b
strain
hiv
thought
virus
pathogen
strain
therefor
harbing
aid
chickenandegg
dilemma
would
argu
strain
opportunist
infect
emerg
immun
control
diminish
virus
appear
rel
unfit
persontoperson
transmiss
sensit
immun
control
particularli
humor
immun
emerg
howev
may
well
exacerb
immun
defici
analog
persist
viru
infect
colleagu
paul
griffith
shown
cytomegaloviru
opportunist
driver
aid
anoth
puzzl
simian
natur
infect
siv
eg
chimpanze
mangabey
sustain
viral
replic
without
becom
ill
one
differ
hiv
human
sivmac
macaqu
induc
chronic
immun
activ
danger
signal
lead
eventu
immun
exhaust
intrigu
model
differ
possibl
mimicri
hiv
envelop
region
human
major
histocompat
complex
molecul
number
differ
host
protein
affect
suscept
infect
hiv
progress
aid
class
class
ii
major
histocompat
antigen
polymorph
human
popul
allel
predispos
diseas
other
reduc
risk
infect
progress
hand
restrict
factor
discov
macaqu
polymorph
human
act
restrict
zoonos
risk
siv
transfer
human
despit
report
human
singl
nucleotid
polymorph
snp
appear
mark
affect
hiv
aid
similarli
human
variat
gene
restrict
factor
reveal
major
chang
suscept
vif
protein
strain
seem
abl
abrog
restrict
effect
recent
whole
genom
scan
reveal
addit
polymorph
associ
hiv
suscept
although
care
need
taken
distinguish
linkag
known
risk
gene
contrast
uncertainti
genet
polymorph
human
suppress
chemokin
receptor
major
effect
suscept
hiv
infect
rate
progress
aid
dramat
illustr
receptor
polymorph
came
rapidli
discoveri
major
coreceptor
hiv
found
sever
longterm
expos
uninfect
peopl
unprotect
sexual
relationship
hiv
partner
homozyg
basepair
delet
gene
homozygot
live
good
health
without
function
protein
genet
resist
infect
hiv
homozyg
individu
becam
hivposit
carri
variant
viru
individu
heterozyg
suscept
infect
although
probabl
lower
risk
significantli
slower
rate
diseas
progress
mutat
found
caucasian
european
descent
specul
whether
previou
pandem
pathogen
smallpox
plagu
might
select
mutat
high
frequenc
european
strong
evid
implic
particular
pathogen
mention
earlier
cc
chemokin
compet
hiv
interact
receptor
therefor
higher
plasma
level
chemokin
lower
densiti
target
cell
surfac
greater
effect
ligandreceptor
modul
hiv
particular
vari
gene
copi
number
across
human
popul
wherea
snp
promot
affect
level
coreceptor
express
sunil
ahuja
group
texa
shown
synergist
effect
high
low
delay
diseas
progress
fig
biggest
disappoint
field
hiv
research
failur
date
develop
efficac
vaccin
prevent
infect
neither
envelopebas
vaccin
design
elicit
neutral
antibodi
dna
vectorbas
vaccin
design
prime
boost
cellmedi
immun
shown
efficaci
field
trial
fact
strong
immun
respons
adenoviru
vector
carri
hiv
immunogen
gene
may
exacerb
risk
hiv
infect
howev
instanc
protect
macaqu
passiv
transfus
antibodi
protect
challeng
homolog
siv
strain
xenogen
allogen
cellbas
vaccin
effect
broader
protect
live
attenu
siv
strain
eg
delet
nef
protect
adult
macaqu
challeng
virul
strain
although
mechan
protect
yet
elucid
satisfactorili
anecdot
evid
small
proport
sex
worker
african
citi
acquir
protect
immun
attract
lot
twentyf
year
hiv
attent
protect
appear
shortliv
went
game
sheer
variabl
million
variant
million
current
infect
peopl
fig
mean
vaccineinduc
immun
need
broadli
reactiv
least
within
clade
common
featur
among
myriad
strain
eg
bind
site
even
epitop
vari
exampl
deni
burton
recogn
bind
site
broadli
crossneutr
human
mab
describ
date
neutral
clade
c
isol
none
clade
circul
recombin
form
ag
grow
interest
therapeut
vaccin
although
prefer
term
immunotherapi
given
progress
aid
control
signific
degre
antiretrovir
drug
idea
improv
immun
respons
act
synergist
antiretrovir
therapi
one
idea
might
achiev
encourag
natur
immun
mechan
allow
drug
holiday
temporari
resurg
viraemia
act
boost
yield
promis
result
anoth
immun
infect
peopl
modifi
hiv
antigen
made
appear
foreign
idea
akin
immunotherapi
cancer
earli
say
whether
approach
benefici
scientif
studi
hiv
aid
past
year
fascin
fig
led
prevent
blood
screen
highli
success
antiretrovir
therapi
major
infect
peopl
access
treatment
led
us
better
understand
complex
human
immun
system
led
cure
infect
yet
realli
promis
lead
microbicid
vaccin
debat
especi
among
aid
activist
whether
suffici
research
fund
spent
therapeut
order
treat
current
infect
peopl
oppos
prophylact
vaccin
order
protect
futur
gener
happili
cumul
fund
govern
charit
foundat
pharmaceut
compani
avail
aid
research
develop
stumbl
block
today
need
littl
humil
face
insidi
foe
hiv
intens
extens
investig
startl
perhap
serendipit
breakthrough
